Monthly research recap
Ketamine research: October 2026
What October 2026's 25 new studies found, synthesized from the papers below. All Ketamine research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ketamine, racemic ketamine, arketamine, R-ketamine, then ranked by relevance.
Research indexed in October 2026 on ketamine was broad and mostly early-stage: clinical work continued to support rapid antidepressant and anti-suicidal effects of low-dose ketamine/esketamine (including in adolescents receiving ECT and in repeated oral dosing for chronic suicidality), while mechanistic, animal, and real-world studies explored brain entropy, stress-axis and glial signaling, cost-effectiveness, and safety signals such as urinary symptoms and suicidality fluctuations. Results are directionally consistent for antidepressant benefit but come largely from small, open-label, interim, retrospective, or animal samples, so durability, blinding, and long-term safety remain unresolved.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Evaluating whether a therapeutic dose of ketamine exposure during adolescence influences adult vulnerability in rats to commonly abused drugs. 2026 | controlled animal experiment | No effect | Seven days of adolescent ketamine (10 mg/kg) did not increase adult ethanol consumption or cocaine place preference in either sex. | |
| Low-dose ketamine modulates brain entropy in treatment-resistant depression: Results from two neuroimaging clinical trials. 2026 | secondary analysis of two RCTs | Supports | Low-dose ketamine increased brain entropy from baseline to day 3 in frontolimbic, cerebellar, and neuromodulatory regions, which the authors suggest may relate to rapid antidepressant effects. | |
| Esketamine-Associated Lower Urinary Tract Symptoms Suggestive of Bladder Overactivity in Treatment-Resistant Depression: A Case Report 2026 | case study | 1 | Opposes | A patient developed urinary urgency and pelvic discomfort after starting intranasal esketamine, with symptoms resolving after dosing was spaced out. |
| Treatment Response Following Repeated Low-Dose Oral Ketamine in Adults with Chronic Suicidality 2026 | open-label pilot study (thesis) | 32 | Supports | Weekly low-dose oral ketamine for six weeks was associated with reduced suicidal ideation in 69% of participants and tolerable side effects, with early response predicting later response. |
| Effects of Social Isolation on the Behavior of Wistar Rats Subjected to a Ketamine-Induced Model of Schizophrenia 2026 | experimental animal study | 144 | Mixed | Ketamine increased locomotion and reduced rearing (more so in females), while social isolation produced separate, largely independent behavioral effects with no ketamine-by-isolation interaction. |
| Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis 2026 | cost-effectiveness analysis | Supports | In a 29-week model, racemic ketamine yielded slightly more QALYs (0.024) at lower health-care and societal costs than ECT and was cost-effective in nearly all sensitivity analyses. | |
| A ketamine derivative exerts enhanced antidepressant effects via adenosine signaling. 2026 | preclinical animal study | Supports | A single 2 mg/kg dose of the ketamine derivative 3C-DCK produced antidepressant-like effects lasting up to 72 hours, longer than ketamine, without hyperlocomotion or ataxia, attributed to adenosine signaling. | |
| Targeting NMDAR2A in microglia: esketamine suppresses M1 polarization in BV2 cells. 2026 | in vitro cell study | Supports | Esketamine suppressed LPS-induced M1 microglial polarization and pro-inflammatory cytokine expression via NMDAR2A, mTOR, and BDNF-TrkB signaling. | |
| Subanesthetic-dose esketamine-assisted electroconvulsive therapy for suicidal ideation in adolescents with major depressive disorder: Interim trial results 2026 | randomized double-blind controlled trial (interim) | 113 | Supports | Adjunctive esketamine (0.25 mg/kg) during ECT produced faster reduction in suicidal ideation and higher response rates (76.8% vs 57.9%) than saline, with similar remission rates and no short-term cognitive decline. |
| Integrating multi-receptor and neuron–glia mechanisms of ketamine's antidepressant action: a convergence framework for understanding efficacy 2026 | review | Unclear | Argues that ketamine's antidepressant efficacy likely arises from convergent multi-receptor and neuron-glia actions, and that many components of this model remain hypothetical. | |
| What is the efficacy of low-dose ketamine for treating depression and other mental health conditions? 2026 | review | Supports | Reports moderate efficacy of ketamine as a rapid-acting treatment for treatment-resistant and bipolar depression, with monitoring needed given limited long-term safety data. | |
| Chronic High‐Dose Ketamine Fails to Induce a Cystitis‐Like Phenotype in Mice Despite High Urinary Metabolite Levels 2026 | controlled animal experiment | 40 | No effect | Twelve weeks of high-dose ketamine (100 mg/kg) produced high urinary and plasma metabolite levels but no cystitis-like voiding, sensory, or histopathological changes versus saline. |
| Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study. 2026 | retrospective cohort study | 80 | Mixed | Mean suicidality decreased modestly, upward and downward transitions occurred at similar rates, but a minority showed transient or sustained worsening and one suicide occurred. |
| Neural correlates of ketamine-induced dilation of temporal expectation 2026 | observational animal study | 2 | Supports | Subanesthetic ketamine caused dose-dependent dilation of time estimation, paralleled by flattened anticipatory ramping and rotated population activity in parietal area LIP. |
| Quality of Life in Patients with Treatment-Resistant Depression Treated with Intranasal Esketamine as Add-On Therapy to an SSRI—A Prospective, Comparative Study in Real-World Clinical Practice 2026 | prospective observational cohort | 60 | Supports | Both groups improved in quality of life and depressive severity, with larger absolute changes in the esketamine add-on group, though the authors caution against causal interpretation. |
| Depression: Ketamine quiets an unruly habenula. 2026 | commentary | Supports | Describes evidence that the ~24-hour window of ketamine's antidepressant effects coincides with reduced habenula activation and reduced aversive learning in healthy subjects. | |
| Subanesthetic ketamine modulates region-specific neural and endocrine responses to acute stress in rats. 2026 | controlled experimental animal study | Supports | Subanesthetic ketamine (15 mg/kg) reduced immobility and attenuated stress-induced corticosterone increases, with region-specific and context-dependent c-Fos changes. | |
| Feeling safe: an empirical-ethical analysis of vulnerability in (es)ketamine treatment 2026 | qualitative study | 24 | Unclear | Argues that feeling safe in (es)ketamine treatment is relationally created through therapeutic presence, grounding, and transitional support, and that patient and clinician models of the treatment can diverge. |
| Peripartum Esketamine: A Narrative Review of Analgesia, Postpartum Depressive Symptoms, Sleep-Related Outcomes, and Safety. 2026 | narrative review | Mixed | Evidence is most consistent for short-term analgesic benefit of peripartum esketamine, with some trials suggesting reduced early postpartum depressive symptoms, but routine prophylactic use is not supported and long-term safety data are insufficient. | |
| Ketamine administration reduced conditioned defensive behaviour and upregulated protein expression associated with neuroplasticity in a planarian model of aversive memory reactivation. 2026 | preclinical experimental study | 15 | Supports | 10 μM ketamine reduced defensive behaviors during aversive memory reactivation and was associated with proteomic enrichment of neuroplasticity-related pathways. |
| Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex 2026 | experimental animal study | Supports | A single 15 mg/kg esketamine dose alleviated pain hypersensitivity, behavioral despair, and anhedonia, associated with Wnt4-related and GSK3β-mTOR signaling changes in the anterior cingulate cortex. | |
| Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study 2026 | retrospective chart review | 72 | No effect | BDI-II response favored IV over SC esketamine after six sessions but was not statistically significant (p=0.059), and endpoint response did not differ; dissociation was more frequent with IV. |
| Adjunctive ketamine for affective symptoms, craving, and relapse prevention in opioid use disorder: protocol for a randomised, double-blind, placebo-controlled clinical trial 2026 | clinical trial protocol | Unclear | Describes a planned double-blind placebo-controlled trial of six IV ketamine infusions (0.5 mg/kg) targeting depressive symptoms and relapse-related outcomes in opioid use disorder. | |
| French psychiatric caregivers' perceptions of psychedelics: A national survey. 2026 | cross-sectional survey | 298 | Mixed | 53% rated the therapeutic benefit-risk ratio of psychedelics favorably while 61% rated recreational use as dangerous, and favorable therapeutic views were associated with clinical practice with ketamine. |
| Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder 2026 | longitudinal observational study | 10 | Supports | Depressive symptoms improved markedly after ketamine-assisted psychotherapy, alongside exploratory DNA methylation changes enriched for NOTCH1-related pathways, which the authors say do not establish causality. |
Points of agreement
- Multiple clinical reports support rapid antidepressant and anti-suicidal effects of low-dose ketamine or esketamine, including in treatment-resistant depression and in adolescents receiving ECT.
- Animal and in vitro work consistently points to neuroplastic, glial, and stress-axis mechanisms underlying ketamine's effects.
- Several sources note that long-term safety and durability data remain limited, warranting monitoring and cautious patient selection.
Conflicts
- Urinary safety signals conflict: a case report links intranasal esketamine to bladder-overactivity symptoms, while a chronic high-dose mouse study found no cystitis-like phenotype.
- Suicidality outcomes differ in emphasis: one open-label trial reports substantial ideation reduction, while a retrospective cohort finds modest mean improvement with frequent upward and downward transitions and some worsening.
- Real-world comparative data are equivocal: one cohort shows larger quality-of-life gains with esketamine add-on, while a retrospective comparison of IV versus SC routes finds no significant response difference.
Gaps
- Long-term durability and safety of repeated ketamine/esketamine dosing are largely unestablished.
- Many clinical findings come from small, open-label, interim, retrospective, or non-randomized samples with confounding risk.
- Blinding integrity and placebo control are rarely addressed in the clinical reports.
- Pediatric, peripartum, and opioid-use-disorder populations remain understudied, with some work still at protocol stage.
- Mechanistic models (multi-receptor, adenosine, glial) remain largely preclinical and require in vivo verification.